Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors

被引：3
作者：
Mahmood, Umair [1 ,2 ]
Lorch, Jochen H. [3 ]
机构：
[1] Dana Farber Canc Inst, Ctr Head & Neck Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER CYTOPATHOLOGY | 2022年 / 130卷 / 01期
关键词：
RADIOACTIVE IODINE; EFFICACY; LAROTRECTINIB; MULTICENTER; EVEROLIMUS;
D O I：
10.1002/cncy.22516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：8 / 11
页数：4
相关论文
共 17 条
[1]  
Blueprint Medicines Corporation, GAVRETO PRALSETINIB
[2]   Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial [J].
Brose, Marcia S. ;
Cabanillas, Maria E. ;
Cohen, Ezra E. W. ;
Wirth, Lori J. ;
Riehl, Todd ;
Yue, Huibin ;
Sherman, Steven I. ;
Sherman, Eric J. .
LANCET ONCOLOGY, 2016, 17 (09) :1272-1282
[3]   Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].
Brose, Marcia S. ;
Nutting, Christopher M. ;
Jarzab, Barbara ;
Elisei, Rossella ;
Siena, Salvatore ;
Bastholt, Lars ;
de la Fouchardiere, Christelle ;
Pacini, Furio ;
Paschke, Ralf ;
Shong, Young Kee ;
Sherman, Steven I. ;
Smit, Johannes W. A. ;
Chung, John ;
Kappeler, Christian ;
Pena, Carol ;
Molnar, Istvan ;
Schlumberger, Martin J. .
LANCET, 2014, 384 (9940) :319-328
[4]   Larotrectinib treatment of advanced TRK fusion thyroid cancer [J].
Cabanillas, M. E. ;
Drilon, A. ;
Farago, A. F. ;
Brose, M. S. ;
McDermott, R. ;
Sohal, D. ;
Oh, D-Y. ;
Almubarak, M. ;
Bauman, J. ;
Chu, E. ;
Kummar, S. ;
Leyvraz, S. ;
Park, K. ;
Reeves, J. A. ;
Dima, L. ;
Maeda, P. ;
Rodrigues, L. ;
Brega, N. ;
Hong, D. S. ;
Waguespack, S. G. .
ANNALS OF ONCOLOGY, 2020, 31 :S1086-S1086
[5]   Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) [J].
Gervais, R ;
Ducolone, A ;
Breton, JL ;
Braun, D ;
Lebeau, B ;
Vaylet, F ;
Debieuvre, D ;
Pujol, JL ;
Tredaniel, J ;
Clouet, P ;
Quoix, E .
ANNALS OF ONCOLOGY, 2005, 16 (01) :90-96
[6]   Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study [J].
Hanna, Glenn J. ;
Busaidy, Naifa L. ;
Chau, Nicole G. ;
Wirth, Lori J. ;
Barletta, Justine A. ;
Calles, Antonio ;
Haddad, Robert I. ;
Kraft, Stefan ;
Cabanillas, Maria E. ;
Rabinowits, Guilherme ;
O'Neill, Anne ;
Limaye, Sewanti A. ;
Alexander, Erik K. ;
Moore, Francis D., Jr. ;
Misiwkeiwicz, Krystof ;
Thomas, Tom ;
Nehs, Matthew ;
Marqusee, Ellen ;
Lee, Stephanie L. ;
Janne, Pasi A. ;
Lorch, Jochen H. .
CLINICAL CANCER RESEARCH, 2018, 24 (07) :1546-1553
[7]   Everolimus in Anaplastic Thyroid Cancer: A Case Series [J].
Harris, Ethan J. ;
Hanna, Glenn J. ;
Chau, Nicole ;
Rabinowits, Guilherme ;
Haddad, Robert ;
Margalit, Danielle N. ;
Schoenfeld, Jonathan ;
Tishler, Roy B. ;
Barletta, Justine A. ;
Nehs, Matthew ;
Janne, Pasi ;
Huang, Julian ;
Groden, Phillip ;
Kacew, Alec ;
Lorch, Jochen .
FRONTIERS IN ONCOLOGY, 2019, 9
[8]   A Tumor-Agnostic NTRK (TRK) Inhibitor [J].
Huang, Franklin W. ;
Feng, Felix Y. .
CELL, 2019, 177 (01) :8-8
[9]   A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes [J].
Lim, S. M. ;
Chang, H. ;
Yoon, M. J. ;
Hong, Y. K. ;
Kim, H. ;
Chung, W. Y. ;
Park, C. S. ;
Nam, K. H. ;
Kang, S. W. ;
Kim, M. K. ;
Kim, S. B. ;
Lee, S. H. ;
Kim, H. G. ;
Na, I. I. ;
Kim, Y. S. ;
Choi, M. Y. ;
Kim, J. G. ;
Park, K. U. ;
Yun, H. J. ;
Kim, J. H. ;
Cho, B. C. .
ANNALS OF ONCOLOGY, 2013, 24 (12) :3089-3094
[10]  
Rolfo CD, 2020, J CLIN ONCOL, V38
12